DOLUTEGRAVIR SODIUM AND LAMIVUDINE

3600 reported adverse events

Drug classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking DOLUTEGRAVIR SODIUM AND LAMIVUDINE:

# Side effect Count
0 PRODUCT DOSE OMISSION ISSUE 1096
1 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 256
2 PRODUCT DOSE OMISSION IN ERROR 224
3 PRODUCT USE ISSUE 195
4 ANXIETY 155
5 PAIN 142
6 DRUG INEFFECTIVE 137
7 RASH 126
8 FATIGUE 122
9 VIRAL LOAD INCREASED 121
See all common reactions for DOLUTEGRAVIR SODIUM AND LAMIVUDINE

DOLUTEGRAVIR SODIUM AND LAMIVUDINE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CYSTOSTOMY 15 0.2679
1 PROCTITIS CHLAMYDIAL 2 0.1818
2 PROCTITIS BACTERIAL 2 0.1250
3 SYPHILIS TEST POSITIVE 3 0.1000
4 CD4 LYMPHOCYTE PERCENTAGE DECREASED 4 0.0909
5 FISTULOTOMY 2 0.0741
6 BLADDER ULCER 3 0.0732
7 HORMONE-DEPENDENT PROSTATE CANCER 5 0.0714
8 BLOOD ELASTASE DECREASED 1 0.0556
9 MONKEYPOX 15 0.0543
See all enriched reactions for DOLUTEGRAVIR SODIUM AND LAMIVUDINE